Eosinophilic myeloid neoplasms

Current Opinion in Hematology

Volumn 20, Issue 2, 2013, Pages 157-162

  Noel, Pierre ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

eosinophilia; hypereosinophilic syndrome; myeloproliferative neoplasms; PDGFRA; PDGFRB

Indexed keywords

ALPHA INTERFERON; CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; JANUS KINASE 2; MIDOSTAURIN; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO ACID SUBSTITUTION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; EOSINOPHILIA; EOSINOPHILIC MYELOPROLIFERATIVE NEOPLASM; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EOSINOPHILIA; HUMANS; HYPEREOSINOPHILIC SYNDROME; MYELOPROLIFERATIVE DISORDERS; PROTEIN-TYROSINE KINASES;

EID: 84873375514     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32835d81bf     Document Type: Review

References (63)

1. Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophilic disorders: a review of recent developments in the field. Expert Rev Hematol 2012; 5:157-176.
2. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201-1214.
3. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22:1999-2010.
4. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102:3093-3096.
5. Bain BJ, Gilliland DG, Horny HP, et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow S, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp. 68-73.
6. Bain BJ, Gilliland DG, Horny HP, et al. Chronic eosinophilic leukaemia, not otherwise specified. In: Swerdlow S, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp. 51-53.
7. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65:2662-2667.
8. Vu HA, Xinh PT, Masuda M, et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006; 20:1414-1421.
9. Noel P. Eosinophilic myeloid disorders. Semin Hematol 2012; 49:120-127.
10. Gleich GJ, Leiferman KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359:1577-1578.
11. Ault P, Cortes J, Koller C, et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002; 26:881-884.
12. Score J, Walz C, Jovanovic JV, et al. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. Leukemia 2009; 23:332-339.
13. Walz C, Curtis CE, Schnittger S, et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006; 45:950-956.
14. Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukemia. Br J Haematol 2007; 138:77-81.
15. Fink SR, Belongie KJ, Paternoster SF, et al. Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. Leuk Res 2009; 33:843-846.
16. Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20:827-832.
17. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007; 21:1183-1188.
18. Elling C, Erben P, Walz C, et al. Novel imatinib-sensitive PDGFRAactivating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011; 117:2935-2943.
19. Erben P, Gosenca D, Muller MC, et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 2010; 95:738-744.
20. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660-4666.
21. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (\+) chronic eosinophilic leukemias. Leukemia 2004; 18:734-742.
22. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124:1319-1325.
23. Burgstaller S, Kreil S, Waghorn K, et al. The severity of FIP1L1-PDGFRApositive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia 2007; 21:2428-2432.
24. Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102:3456-3457; author reply 3457.
25. Sato Y, Taniguchi R, Yamada T, et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive noninvasive marker of cardiac disorder. Intern Med 2000; 39:350.
26. Reiter A, Walz C, Cross NC. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets 2007; 8:205-216.
27. Klion AD. Eosinophilic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2011; 2011:257-263.
28. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol 2000; 86:110-113.
29. Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:457-475.
30. Kanno H, Ouchi N, Sato M, et al. Hypereosinophilia with systemic thrombophlebitis. Hum Pathol 2005; 36:585-589.
31. Liapis H, Ho AK, Brown D, et al. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int 2005; 67:1806-1811.
32. Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002; 99:10700-10705.
33. Gotlib J. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87:904-914.
34. Helbig G, Stella-Holowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008; 141:200-204.
35. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109:4635-4640.
36. Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007; 110:3552-3556.
37. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92: 1173-1179.
38. Imagawa J, Harada Y, Yoshida T, et al. Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib. Rinsho Ketsueki 2011; 52:546-550.
39. Tabouret E, Charbonnier A, Mozziconacci MJ, Ivanov V. Low-dose nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Leuk Res 2011; 35:136.
40. Simon D, Salemi S, Yousefi S, Simon HU. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 2008; 121:1054-1056.
41. Von Bubnoff N, Gorantla SP, Engh RA, et al. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene 2011; 30:933-943.
42. Metzgeroth G, Erben P, Martin H, et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia. 2012; 26:162-164.
43. Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009; 23:845-851.
44. Halaburda K, Prejzner W, Szatkowski D, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2006; 38:319-320.
45. Juvonen E, Volin L, Koponen A, Ruutu T. Allogeneic blood stem cell transplantation following nonmyeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant 2002; 29:457-458.
46. Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful nonmyeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002; 119:131-134.
47. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104:3038-3045.
48. Schoffski P, Ganser A, Pascheberg U, et al. Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. Ann Hematol 2000; 79:95-98.
49. Maric I, Robyn J, Metcalfe DD, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007; 120:680-687.
50. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognsostic factors. Blood 2009; 113:5727-5736.
51. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cell s and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108:2366-2372.
52. Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (mast cell disease). In: Swerdlow S, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp. 51-53.
53. Ma Y, Zeng S, Metcalfe DD, et al. The KIT mutation causing human mastocytosis is ressitant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wildtype kinases and those with regulatory-type mutations. Blood 2002; 99:1741-1744.
54. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77:307-316.
55. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347:481-487.
56. Nand R, Bryke C, Kroft SH, et al. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res 2009; 33:1144-1146.
57. Aguiar RC, Macdonald D, Mason PJ, et al. Myeloproliferative disorder associated with 8p11 translocations. Blood 1995; 86:834-835.
58. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010; 41:461-476.
59. Chen J, Deangelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101:14479-14484.
60. Olivier JW, Deol I, Morgan DL, et al. Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, litterature review and report of a case with a unique chromosomal abnormality. Br J Haematol 1996; 92:176-183.
61. HelbigG, Soja A, Bartkoeska-Chrobok A, et al. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol 2012; 87:643-645.
62. Luciano L, Catalano L, Sarrantonio C, et al. Alpha IFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica 1999; 84:651-653.
63. Malbrain ML, Van den Bergh H, Zachee P. Further evidence for a clonal nature of the idiopathic hypereosinophilic syndrome: complete hematologic and cytogenetic remission induced by interferon-alpha in a case of unique chromosomal abnormality. Br J Haematol 1996; 92:175-183.